Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.

IF 58.7 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Nature Medicine Pub Date : 2024-11-15 DOI:10.1038/s41591-024-03404-w

Steven M Horwitz, Ajit J Nirmal, Jahan Rahman, Ran Xu, Esther Drill, Natasha Galasso, Nivetha Ganesan, Theresa Davey, Helen Hancock, Leslie Perez, Catherine Maccaro, Alexandra Bahgat, Evan Marzouk, Elizabeth Cathcart, Alison Moskowitz, Ariela Noy, Anita Kumar, Eric Jacobsen, David C Fisher, Neha Mehta-Shah, Youn H Kim, Michael Khodadoust, Nikita Kotlov, Anastasia Nikitina, Olga Kudryashova, Valeria Zubareva, Ksenia Zornikova, Nara Shin, Maria Sorokina, Sandrine Degryse, Ekaterina Postovalova, Aleksander Bagaev, Kinga Hosszu, Devin McAvoy, Jaap J Boelens, Wenchao Wu, Zoe Ciantra, Jackson W Appelt, Christopher Trevisani, Sam Amaka, David M Weinstock, Santosha A Vardhana

引用次数: 0

查看原文本刊更多论文

作者更正：杜韦利西布联合罗米地辛治疗复发/难治性T细胞淋巴瘤：1b/2a期试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Medicine 医学-生化与分子生物学

CiteScore

100.90

自引率

0.70%

发文量

525

审稿时长

1 months

期刊介绍： Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.